✦ LIBER ✦

Recent advances in etoposide therapy for non-small cell lung cancer

✍ Scribed by Philip Bonomi

Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 504 KB
Volume: 67
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19910101)67:1+<254::aid-cncr2820671308>3.0.co;2-v

No coin nor oath required. For personal study only.

✦ Synopsis

Non-small cell lung cancer (NSCLC) continues to be a major health problem in the US. In 1990, approximately 120,000 new cases will be diagnosed, and the majority of these patients will have either unresectable disease or resected disease that has a relatively low chance of being cured. A variety of chemotherapy treatments have been evaluated in patients with advanced NSCLC. The objective of this review is to summarize the results of the chemotherapy trials in Stage I11 and IV NSCLC patients. Cancer 673254259, 1991.

UNG CANCER CONTINUES to be a major health problem L in the US, with 157,000 new cases and 142,000 deaths predicted in 1990. Approximately 80% of lung cancer patients will have non-small cell lung cancer (NSCLC).

Although surgical treatment provides a relatively high chance of cure for patients with early stages of NSCLC,

📜 SIMILAR VOLUMES

Cisplatin, 5-fluorouracil, and etoposide

Cisplatin, 5-fluorouracil, and etoposide for advanced non-small cell lung cancer

✍ Thomas J. Lynch Jr.; Frederick Kass; Anthony D. Elias; Arthur Skarin; Emil Frei 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 447 KB 👁 2 views

Etoposide in the management of non-small

Etoposide in the management of non-small cell lung cancer

✍ John C. Ruckdeschel 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 387 KB 👁 2 views

Adjuvant therapy of non-small cell lung

Adjuvant therapy of non-small cell lung cancer

✍ E. Carmack Holmes 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 251 KB 👁 2 views

One hundred and forty thousand patients in the United States will develop lung cancer annually. About one half of these will have disease confined to the thorax with no clinical evidence of dissemination (Figure 1). A relatively high proportion of these patients will actually have disease that can b

Simultaneous chemoradiation in advanced

Simultaneous chemoradiation in advanced non-small cell lung cancer

✍ Julianna Pisch; Stephen Malamud; James Harvey; Edward J. Beattie 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 558 KB

We designed our study to evaluate the safety and efficacy of simultaneous chemoradiation therapy in an accelerated, twice-a-day schedule to improve local control and survival in advanced lung cancer patients. Forty-one patients were entered into the study. Twenty-three had stage IIIB and 18 had stag

Chemotherapy of advanced non-small cell

Chemotherapy of advanced non-small cell lung cancer

✍ Bonnie J. Takasugi; Thomas P. Miller 📂 Article 📅 1984 🏛 Springer US 🌐 English ⚖ 711 KB

Etoposide combination therapy for small

Etoposide combination therapy for small cell carcinoma of the lung

✍ R. P. Abratt; P. A. Willcox; R. H. Hewitson 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 191 KB

Sixty-three consecutive patients with small cell carcinoma of the lung were treated by six cycles at 3-week intervals of etoposide 120 mg/m2 i.v. on day 1 and orally on days 2-5, adriamycin 40 mg/m2 i.v. on day 1 and vincristine 1.4 mg/m2 i.v. on day 1. Tumour bed irradiation was administered to pat